FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 216 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Anal Cancer Incidence and Deaths Are Rising in the United States December 19, 2019 ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to... September 18, 2025 Does Living Near Power Lines Increase My Risk of Cancer? March 17, 2022 Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated... April 1, 2025 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Toripalimab Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative... Growing the Cancer Research Pipeline by Expanding Opportunities pCR Correlates with RFS and OS with Neoadjuvant Therapy in Stage...
